Statements:
ATI-450 – pancreatic cancer. darolutamide – metastatic hormone sensitive prostate cancer. mirvetuximab soravtansine – in ovarian cancer. KB-0742 – in MYC-amplified solid tumors. zandelisib – in relapsed/refractory follicular lymphoma. OP-1250 – in ≥4-line ER+/HER2-negative breast cancer.
Compendium (d) Compendium (f)
